Company intelligence / Profile preview

Triplet Therapeutics

Cambridge, Massachusetts, United Statespfizer.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Triplet Therapeutics developed TTX-3360, an antisense oligonucleotide targeting MSH3 in the DNA Damage Response pathway. The company showed proof of mechanism in non-human primates and HD mouse models, but some test results revealed concerning toxicity levels. The company shut down in October 2022 before reaching clinical trials.

Therapeutic areas: Neurology
Modalities: Antisense oligonucleotides (ASOs)small interfering RNA (siRNA)
Industry: Biotech

Drug pipeline

1 asset

TTX-3360

Unknown

Beyond the preview

Go deeper on Triplet Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Triplet Therapeutics.

Explore the full profile